Hepatitis C, Chronic: all 1,090 studies
Page 9 of 11. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC GenotypeTerminatedNCT01384383Phase 2
- HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon SensitivityTerminatedNCT01377909Phase 1
- Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)CompletedNCT01371604Phase 2
- Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus InfectionCompletedNCT01371578Phase 2
- A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis CCompletedNCT01371162Phase 1
- Prediction of Incidence of Liver Cancer by Use of Real-time Tissue ElastographyStatus unknownNCT01360892
- Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver DiseaseStatus unknownNCT01360879
- GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCompletedNCT01356160Phase 2
- GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) InfectionCompletedNCT01353248Phase 2
- An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)CompletedNCT01344889
- HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1bCompletedNCT01342003
- A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination TherapyCompletedNCT01337375Phase 1
- CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) SubjectsStatus unknownNCT01335711Phase 2
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedNCT01332955Phase 2
- A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis CCompletedNCT01331850Phase 2
- Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis CStatus unknownNCT01327729Phase 2/3
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT01316237Phase 1
- Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCVCompletedNCT01310205
- A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)WithdrawnNCT01296971Phase 3
- Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C PatientsCompletedNCT01290965Phase 1
- Ribavirin Dose Optimization for the Treatment of Hepatitis CCompletedNCT01289496Phase 2
- A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)CompletedNCT01278134Phase 2
- Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy VolunteersWithdrawnNCT01274013
- Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis CCompletedNCT01272479
- Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.Status unknownNCT01272310Phase 1/2
- A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01271790Phase 2
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 PatientsCompletedNCT01263860Phase 3
- Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-RespondersCompletedNCT01226446Phase 2
- A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT01225380Phase 2
- A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus InfectionCompletedNCT01220947Phase 2
- Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone MaintenanceCompletedNCT01210404Phase 1
- The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model SystemCompletedNCT01206933
- Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C SubjectsCompletedNCT01200420Phase 2
- An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01200225
- Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.CompletedNCT01195181Phase 4
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CCompletedNCT01194037Phase 1/2
- A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1CompletedNCT01185860Phase 1
- A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1CompletedNCT01181024Phase 1
- Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.CompletedNCT01178996Phase 3
- Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin TreatmentsStatus unknownNCT01178749
- Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?CompletedNCT01159613
- A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)CompletedNCT01157104Phase 1
- Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?Status unknownNCT01151397Not applicable
- Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?Status unknownNCT01146626Not applicable
- Study of VX-985 in Subjects With Chronic Hepatitis CCompletedNCT01144936Phase 1
- A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype IWithdrawnNCT01142700Phase 2
- Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis CCompletedNCT01140997Phase 2
- A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis CCompletedNCT01121731Phase 1/2
- Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid PharmacotherapyCompletedNCT01120795Phase 4
- Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCVCompletedNCT01113814Not applicable
- Biliverdin Reductase A in Chronic Hepatitis C Virus InfectionCompletedNCT01112033
- Chronic Hepatitis C (CHC) - Genotype 3 Infection in CanadaTerminatedNCT01100749
- EXtended Therapy in Hepatitis C Genotype 3 Infected PatientsTerminatedNCT01095445Phase 3
- Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)CompletedNCT01081158Phase 1
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedNCT01080222Phase 2
- Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) PatientsWithdrawnNCT01062659
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4CompletedNCT01057667Phase 2
- PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)Status unknownNCT01056172Phase 4
- Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV PatientsCompletedNCT01055821Phase 2
- Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment FailureCompletedNCT01033045
- The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus RibavirinStatus unknownNCT01025765Phase 4
- Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis CCompletedNCT01018615Phase 1
- Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCompletedNCT01012895Phase 2
- Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)CompletedNCT01011166Phase 2
- Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT01010646Phase 2
- Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus InfectionStatus unknownNCT01001754Phase 2
- ADHEPTA Study: Adherence Questionnaire in Hepatitis CCompletedNCT00998621
- Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical TrialCompletedNCT00983164Not applicable
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected PatientsCompletedNCT00983060Phase 2
- Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis CStatus unknownNCT00980161
- Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C VirusCompletedNCT00971308Phase 1
- Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have RelapsedCompletedNCT00968357Phase 2
- A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT00963885Phase 2
- Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I InfectionTerminatedNCT00962936Phase 1/2
- Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting ConditionsCompletedNCT00960479Phase 1
- Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting ConditionsCompletedNCT00959933Phase 1
- Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian EthnicityCompletedNCT00957866Phase 4
- Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard TherapyWithdrawnNCT00956722Phase 1
- 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)CompletedNCT00953589Phase 2
- Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis CCompletedNCT00948220Phase 4
- High Dose Ribavirin in the Treatment of Chronic Hepatitis CCompletedNCT00944684Phase 2
- A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis CCompletedNCT00940420Phase 4
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis CWithdrawnNCT00930995Phase 2
- Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin ResistanceTerminatedNCT00927290Phase 3
- Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 SubjectsCompletedNCT00926016Not applicable
- Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
- Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis CCompletedNCT00910975Phase 4
- Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV TreatmentCompletedNCT00909129Not applicable
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/RelapsersTerminatedNCT00882193Early Phase 1
- Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant PatientsCompletedNCT00881582Phase 4
- Effects of Genotypes on Interferon Signaling in Chronic Hepatitis CWithdrawnNCT00876174
- Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus InfectionTerminatedNCT00874796Phase 2
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT00869661Phase 2
- Prediction of Hepatitis C Recurrence in Liver Transplant RecipientsTerminatedNCT00867243
- Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCVCompletedNCT00863239Phase 2
- A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNCT00854802Not applicable
- Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral TreatmentCompletedNCT00844272Phase 4
- Impact of Hepatitis C Virus Variability on SteatosisTerminatedNCT00843076
- Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced FibrosisTerminatedNCT00840489Phase 2
- Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular CarcinomaStatus unknownNCT00834860Phase 4